1
|
Zitouni J, Beauchet A, Curmin R, Di Lernia V, Bursztejn AC, Mazereeuw-Hautier J, Gottlieb J, Lasek A, Aubert H, Droitcourt C, Bulai-Livideanu C, Fortina AB, Caroppo F, Quiles-Tsimaratos N, Mallet S, Barthélémy H, Puzenat E, Bouilly-Auvray D, Neri I, Phan C, Mahé E. Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr). Paediatr Drugs 2022; 24:281-292. [PMID: 35397731 DOI: 10.1007/s40272-022-00501-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/13/2022] [Indexed: 12/19/2022]
Abstract
INTRODUCTION Biological therapies are valuable treatments for severe psoriasis. Children aged under 12 years are underrepresented in therapeutic trials for these drugs. The objective of the 'BiPe Jr' cohort study was to evaluate the drug survival, effectiveness, tolerance and switching patterns of biological therapies in children under 12 years of age with psoriasis. METHODS We conducted a multicentre retrospective study of children with psoriasis who received at least one injection of a biological agent, even off-licence, before the age of 12 years in France and Italy, collecting the data between April and August 2021. The data collected were from March 2012 up to August 2021. RESULTS In total, 82 children (mean age: 9.1 years; females: 61.0%) received 106 treatments. The drugs administered were adalimumab (n = 49), etanercept (n = 37), ustekinumab (n = 15), anakinra (n = 2), infliximab (n = 2) and secukinumab (n = 1). The most common form of psoriasis was plaque psoriasis (62.9%). The Physician Global Assessment and the Psoriasis Area Severity Index (PASI) scores decreased significantly from baseline to 3 months after treatment initiation for the three main biological drugs; PASI went from 14.1 ± 9.4 to 4.1 ± 11.3 for adalimumab (p = 0.001), 14.9 ± 9.3 to 5.1 ± 4.0 for etanercept (p = 0.002) and 11.6 ± 8.3 to 2.6 ± 2.2 for ustekinumab (p = 0.007). A trend towards higher 2-year maintenance rates was observed for ustekinumab and adalimumab, compared with etanercept (p = 0.06). 52 children discontinued their biological therapy, most frequently due to inefficacy (n = 28) and remission (n = 14). Seven serious adverse events (SAEs) were reported, including four severe infections. DISCUSSION Our analyses of drug survival and treatment patterns, combined with those of previous studies conducted in older children, indicate that there is a trend towards higher 2-year survival rates of ustekinumab and adalimumab. The SAEs identified were rare, but highlight the need for increased vigilance concerning infections. Overall, the biological therapies showed good effectiveness and safety profiles when used in daily practice for the treatment of young children with psoriasis.
Collapse
Affiliation(s)
- Jinane Zitouni
- Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France
| | - Alain Beauchet
- Public Health Department, Centre Hospitalier Universitaire Ambroise Paré, Boulogne-Billancourt, France
| | - Raphaëlle Curmin
- Sorbonne University, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - Vito Di Lernia
- Dermatology unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy
| | - Anne-Claire Bursztejn
- Dermatology Department, Hôpitaux de Brabois, Centre Hospitalier Universitaire de Nancy, Vandoeuvre-lès-Nancy, France
| | - Juliette Mazereeuw-Hautier
- Dermatology Department, Centre de référence des maladies rares de la peau et des muqueuses, Hôpital Larrey, Toulouse, France
| | - Jérémy Gottlieb
- Immunology and Dermatology Department, Hôpital Bicêtre, CHU de Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Le Kremlin Bicêtre, France
| | - Audrey Lasek
- Dermatology Department,, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
| | - Hélène Aubert
- Dermatology Department, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Catherine Droitcourt
- Dermatology Department, Centre Hospitalier Universitaire Pontchaillou, Rennes, France
| | | | - Anna Belloni Fortina
- Pediatric Dermatology Unit, Department of Medicine DIMED, University of Padova, Padua, Italy
| | - Francesca Caroppo
- Pediatric Dermatology Unit, Department of Medicine DIMED, University of Padova, Padua, Italy
| | | | - Stéphanie Mallet
- Dermatology Department, Hôpital de la Timone, Assistance-publique-Hôpitaux de Marseille, Marseille, France
| | - Hugues Barthélémy
- Dermatology Department, Centre Hospitalier d'Auxerre, Auxerre, France
| | - Eve Puzenat
- Dermatology Department, Centre Hospitalier Universitaire Saint-Jacques, Besançon, France
| | | | - Iria Neri
- Dermatology, Department of Experimental, Diagnostic, and Specialty Medicine, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Céline Phan
- Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France
| | - Emmanuel Mahé
- Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France.
| | | |
Collapse
|
2
|
Grodner C, Beauchet A, Fougerousse AC, Quiles-Tsimaratos N, Perrot JL, Barthelemy H, Parier J, Maccari F, Bénéton N, Bouilly-Auvray D, Ruer-Mulard M, Boulard C, Jacobzone C, Thomas-Beaulieu D, Méry-Bossard L, Pourchot D, Chaby G, Girard C, Duval-Modeste AB, Vermersch-Langlin A, Delaunay J, Marc S, Kemula M, Sigal ML, Amy de la Breteque M, Steff M, Bilan P, Liégeon AL, Aubert H, Solyga B, Kluger N, Mahé E. Complications des tatouages chez les patients psoriasiques avec ou sans traitements. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
3
|
Fougerousse AC, Reguiai Z, Maccari F, Parier J, Schmutz JL, Begon E, Chaby G, Bouilly-Auvray D, Pallure V, Beneton N, Monfort JB, Boulard C, Delaunay J, Clément Lepley C, Bastien M, Mery Bossard L, Perrot JL, Jacobzone C, Vermersch A, Esteve E. Profil des patients à l’initiation du guselkumab : étude rétrospective multicentrique. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
4
|
Amy de la Breteque M, Beauchet A, Quiles-Tsimaratos N, Estève E, Le Guyadec T, Ruer-Mulard M, Maccari F, Reguiai Z, Girard C, Bastien M, Avenel-Audran M, Pauwels C, Bouilly-Auvray D, Sigal ML, Mahé E. Characteristics of patients with plaque psoriasis who have discordance between Psoriasis Area Severity Index and dermatology life quality index scores. J Eur Acad Dermatol Venereol 2016; 31:e269-e272. [DOI: 10.1111/jdv.14021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | - A. Beauchet
- Department of Public Health; Centre Hospitalier Universitaire Ambroise Paré; Assistance Publique- Hôpitaux de Paris; Boulogne Billancourt France
| | | | - E. Estève
- Department of Dermatology; Centre Hospitalier Régional d'Orléans; Orléans France
| | - T. Le Guyadec
- Department of Dermatology; Hôpital d'Instruction des Armées Percy; Clamart France
| | | | - F. Maccari
- Department of Dermatology; Hôpital d'Instruction des Armées Bégin; Saint-Mandé France
| | - Z. Reguiai
- Department of Dermatology; Hôpital Robert Debré; Reims France
| | - C. Girard
- Department of Dermatology; Hôpital Saint-Eloi; Montpellier France
| | - M. Bastien
- Private Office; Joinville le Pont France
| | - M. Avenel-Audran
- Department of Dermatology; Centre Hospitalier Universitaire; Angers France
| | - C. Pauwels
- Department of Dermatology; Centre Hospitalier Universitaire; Hôpital du Bocage; Dijon France
| | - D. Bouilly-Auvray
- Department of Dermatology; Centre Hospitalier Intercommunal Poissy/St Germain en Laye; St Germain en Laye France
| | - M.-L. Sigal
- Department of Dermatology; Hôpital Victor Dupouy Hospital; Argenteuil France
| | - E. Mahé
- Department of Dermatology; Hôpital Victor Dupouy Hospital; Argenteuil France
| | | |
Collapse
|
5
|
Amy De La Breteque M, Sigal ML, Estève E, Le Guyadec T, Maccari F, Reguiai Z, Bastien M, Avenel-Audran M, Boyé T, Mery-Bossart L, Bravard P, Pauwels C, Bouilly-Auvray D, Gener G, Beauchet A, Mahé E. Évaluation des paramètres expliquant la discordance PASI/DLQI chez les patients atteints de psoriasis. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
6
|
Mahé E, Maccari F, Beauchet A, Estève E, Reguiai Z, Le Guyadec T, Quiles-Tsimaratos N, Averel-Audran M, Boyer T, Goujon-Henry C, Bravard P, Bouilly-Auvray D, Bastien M, Mery-Brossard L, Géner G, Pauwels C, Sigal ML. Évaluation du parcours de soins avant une première consultation pour un psoriasis. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|